Hospital
Fort Walton Beach Medical Center, INC.
Fort Walton Beach Medical Center, INC. was paid $10.30M by Medicaid between Jan 2018 and Dec 2024, across 182 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoFORT WALTON BEACH MEDICAL CENTER, INC.
FT WALTON BEACH, FL 32547
FT WALTON BEACH, FL 32547
33aNPI1639128820assigned 05/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.30M
24GClaims463,993
24DCodes billed182
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#50 of 163
Median peer was paid$4.77M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,263 | $340K | |
| 2019 | 103,431 | $1.63M | |
| 2020 | 77,970 | $1.15M | |
| 2021 | 93,622 | $1.91M | |
| 2022 | 94,842 | $2.74M | |
| 2023 | 43,871 | $1.74M | |
| 2024incomplete | 13,994 | $793K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 45,988 | 40,893 | $3.53M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 24,113 | 19,605 | $1.30M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.2% | 11,679 | 10,797 | $949K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.6% | 11,645 | 2,308 | $675K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 3,079 | 2,689 | $381K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.5% | 3,703 | 3,447 | $358K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 3,762 | 3,064 | $274K |
| 80053 | Comprehensive metabolic panel | 2.4% | 18,655 | 14,474 | $248K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.1% | 11,429 | 8,805 | $221K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 5,113 | 4,224 | $194K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 4,930 | 3,994 | $184K |
| C1729 | Catheter, drainage | 1.6% | 9,848 | 8,331 | $161K |
170 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.3% | 7,998 | $139K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 948 | $109K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,871 | $100K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,232 | $92K |
| 81003 | <1% | 22,181 | $78K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,729 | $77K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 671 | $68K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,786 | $65K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,655 | $52K |
| 76801 | <1% | 1,014 | $51K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,575 | $50K |
| 93976 | <1% | 1,328 | $44K | |
| 97602 | <1% | 654 | $43K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,493 | $42K |
| 59025 | Fetal non-stress test | <1% | 1,482 | $42K |
| G0378 | Hospital observation service, per hour | <1% | 2,370 | $39K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 289 | $36K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,097 | $34K |
| A9270 | Non-covered item or service | <1% | 9,768 | $30K |
| 81025 | <1% | 8,354 | $28K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,015 | $26K |
| 87040 | <1% | 2,508 | $25K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,231 | $24K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,325 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,124 | $23K |
| 85027 | <1% | 32,840 | $22K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 1,184 | $22K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 2,095 | $22K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 710 | $21K |
| 84702 | <1% | 1,633 | $20K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 500 | $19K |
| 87070 | <1% | 1,012 | $18K | |
| 73610 | <1% | 985 | $17K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 552 | $17K |
| 74018 | <1% | 868 | $17K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,821 | $16K |
| 73630 | <1% | 1,198 | $16K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 423 | $15K |
| 73564 | <1% | 950 | $15K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 766 | $13K |
| 73130 | <1% | 713 | $13K | |
| 97162 | <1% | 402 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,173 | $10K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 538 | $10K |
| 97161 | <1% | 374 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 794 | $8K |
| 85610 | <1% | 3,694 | $7K | |
| 73030 | <1% | 600 | $7K | |
| 73110 | <1% | 501 | $7K | |
| 85730 | <1% | 3,166 | $7K | |
| 80076 | <1% | 5,072 | $7K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 147 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,532 | $6K |
| C1769 | Guide wire | <1% | 107 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,164 | $5K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,144 | $5K |
| 83735 | <1% | 8,600 | $4K | |
| 86850 | <1% | 1,292 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,365 | $4K |
| 97164 | <1% | 179 | $4K | |
| 73080 | <1% | 159 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 256 | $4K |
| 12001 | <1% | 75 | $3K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 129 | $3K |
| 84484 | <1% | 4,383 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,005 | $3K |
| 93971 | <1% | 137 | $3K | |
| 87210 | <1% | 357 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,604 | $3K |
| 83880 | <1% | 2,447 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 610 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,105 | $2K |
| 86900 | <1% | 1,788 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,839 | $2K |
| 84703 | <1% | 1,953 | $2K | |
| 87081 | <1% | 906 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 269 | $2K |
| 12011 | <1% | 60 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,352 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,361 | $2K |
| 83605 | <1% | 1,507 | $2K | |
| 82962 | <1% | 52 | $1K | |
| 80061 | Lipid panel | <1% | 1,478 | $1K |
| 86901 | <1% | 1,839 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,293 | $1K |
| 83690 | <1% | 6,414 | $1K | |
| 87077 | <1% | 553 | $1K | |
| 74019 | <1% | 81 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 592 | $1K |
| 86140 | <1% | 367 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 767 | $955.86 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,429 | $938.20 |
| 72100 | <1% | 156 | $924.91 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,391 | $900.27 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 778 | $836.32 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 49 | $817.84 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,127 | $812.69 |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $811.10 |
| 84439 | <1% | 639 | $782.13 | |
| 90715 | <1% | 554 | $760.54 | |
| 73090 | <1% | 27 | $740.46 | |
| 72170 | <1% | 22 | $739.76 | |
| 86769 | <1% | 1,483 | $735.29 | |
| 85378 | <1% | 1,025 | $701.81 | |
| 84100 | <1% | 779 | $682.82 | |
| 87045 | <1% | 50 | $655.00 | |
| 82950 | <1% | 59 | $616.41 | |
| 70486 | <1% | 42 | $591.11 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,105 | $565.35 |
| 80047 | <1% | 424 | $418.03 | |
| J2704 | Injection, propofol, 10 mg | <1% | 58 | $401.40 |
| 82270 | <1% | 28 | $390.37 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,274 | $348.27 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 698 | $340.50 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 283 | $330.60 |
| 82248 | <1% | 1,459 | $329.84 | |
| 86592 | <1% | 171 | $320.21 | |
| 86703 | <1% | 184 | $300.72 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 18 | $297.36 |
| 87088 | <1% | 1,612 | $297.18 | |
| 86762 | <1% | 91 | $295.73 | |
| 87186 | <1% | 1,755 | $293.72 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 264 | $230.86 |
| 73502 | <1% | 69 | $210.58 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $209.70 |
| 10060 | <1% | 13 | $197.36 | |
| 87340 | <1% | 176 | $159.67 | |
| 82550 | <1% | 278 | $155.57 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,876 | $138.28 |
| 96376 | <1% | 1,006 | $134.35 | |
| 87205 | <1% | 406 | $77.70 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $74.78 |
| 82570 | <1% | 100 | $68.83 | |
| 83020 | <1% | 16 | $43.12 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 248 | $37.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 224 | $25.07 |
| S0028 | Injection, famotidine, 20 mg | <1% | 103 | $21.73 |
| 72131 | <1% | 15 | $20.73 | |
| 82105 | <1% | 13 | $19.86 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 20 | $11.40 |
| 82150 | <1% | 14 | $6.97 | |
| 84157 | <1% | 95 | $6.09 | |
| 85651 | <1% | 64 | $1.98 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 612 | $0.00 |
| 85018 | 0% | 14 | $0.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 75 | $0.00 |
| 81001 | 0% | 192 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 14 | $0.00 |
| 87449 | 0% | 15 | $0.00 | |
| 82803 | 0% | 28 | $0.00 | |
| 84132 | 0% | 15 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 16 | $0.00 |
| 82435 | 0% | 13 | $0.00 | |
| 82330 | 0% | 13 | $0.00 | |
| 88304 | 0% | 12 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 182 | $0.00 |
| 73140 | 0% | 15 | $0.00 | |
| J0558 | Injection, penicillin g benzathine and penicillin g procaine, 100,000 units | 0% | 161 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 82 | $0.00 |
| 87899 | 0% | 60 | $0.00 | |
| 84520 | 0% | 18 | $0.00 | |
| 82947 | 0% | 13 | $0.00 | |
| 82140 | 0% | 13 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 14 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 18 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 12 | $0.00 |
| 84295 | 0% | 13 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 57 | $0.00 |
| 82565 | 0% | 17 | $0.00 | |
| 73590 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENRY, CAMILLE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Galencare, INC. | St Petersburg, FL | $3.56M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.